{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:09:53Z","timestamp":1773814193266,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National key research and Development Program of China","award":["2016YFC0904503"],"award-info":[{"award-number":["2016YFC0904503"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Meningeal carcinomatosis (MC) is the most severe form of brain metastasis and causes significant morbidity and mortality. Currently, the diagnosis of MC is routinely confirmed on the basis of clinical manifestation, positive cerebrospinal fluid (CSF) cytology, and\/or neuroimaging features. However, negative rate of CSF cytology and neuroimaging findings often result in a failure to diagnose MC from the patients who actually have the disease. Here we evaluate the CSF circulating tumor DNA (ctDNA) in the diagnosis of MC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 35 CSF samples were collected from 35 patients with MC for CSF cytology examination, CSF ctDNA extraction and cancer-associated gene mutations detection by next-generation sequencing (NGS) at the same time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The most frequent primary tumor in this study was lung cancer (26\/35, 74%), followed by gastric cancer (2\/35, 6%), breast cancer (2\/35, 6%), prostatic cancer (1\/35, 3%), parotid gland carcinoma (1\/35, 3%) and lymphoma (1\/35, 3%) while no primary tumor could be found in the remaining 2 patients in spite of using various inspection methods. Twenty-five CSF samples (25\/35; 71%) were found neoplastic cells in CSF cytology examination while all of the 35 CSF samples (35\/35; 100%) were revealed having detectable ctDNA in which cancer-associated gene mutations were detected. All of 35 patients with MC in the study underwent contrast-enhanced brain MRI and\/or CT and 22 neuroimaging features (22\/35; 63%) were consistent with MC. The sensitivity of the neuroimaging was 88% (95% confidence intervals [95% CI], 75 to 100) (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u200922\/25) and 63% (95% CI, 47 to 79) (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u200922\/35) compared to those of CSF cytology and CSF ctDNA, respectively. The sensitivity of the CSF cytology was 71% (95% CI, 56 to 86) (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200925\/35) compared to that of CSF ctDNA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests a higher sensitivity of CSF ctDNA than those of CSF cytology and neuroimaging findings. We find cancer-associated gene mutations in ctDNA from CSF of patients with MC at 100% of our cohort, and utilizing CSF ctDNA as liquid biopsy technology based on the detection of cancer-associated gene mutations may give additional information to diagnose MC with negative CSF cytology and\/or negative neuroimaging findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-019-1554-5","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T09:02:39Z","timestamp":1576746159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis"],"prefix":"10.1186","volume":"19","author":[{"given":"Yue","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Ying","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Li","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Su","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Zhao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5861-4916","authenticated-orcid":false,"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"issue":"3","key":"1554_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11910-008-0038-6","volume":"8","author":"MC Chamberlain","year":"2008","unstructured":"Chamberlain MC. Neoplastic meningitis. Curr Neurol Neurosci Rep. 2008;8(3):249\u201358.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"1554_CR2","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.seminoncol.2009.05.005","volume":"36","author":"MC Chamberlain","year":"2009","unstructured":"Chamberlain MC, Glantz M, Groves MD, Wilson WH. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol. 2009;36(2):S35\u201345.","journal-title":"Semin Oncol"},{"issue":"2","key":"1554_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","volume":"104","author":"CRASD Azevedo","year":"2011","unstructured":"Azevedo CRASD, Cruz MRS, Chinen LTD, Peres SV, Peterlevitz MA, Pereira AEDA, et al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neuro-Oncol. 2011;104(2):565\u201372.","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"1554_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/CCO.0b013e32833de986","volume":"22","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol. 2010;22(6):627\u201335. https:\/\/doi.org\/10.1097\/CCO.0b013e32833de986.","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"1554_CR5","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1590\/S0004-282X2011000700024","volume":"69","author":"SJ Martins","year":"2011","unstructured":"Martins SJ, Azevedo CR, Chinen LT, Cruz MR, Peterlevitz MA, Gimenes DL. Meningeal carcinomatosis in solid tumors. Arq Neuropsiquiatr. 2011;69(6):973\u201380.","journal-title":"Arq Neuropsiquiatr"},{"issue":"8","key":"1554_CR6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1212\/WNL.54.8.1670","volume":"54","author":"G Stockhammer","year":"2000","unstructured":"Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurol. 2000;54(8):1670\u20136.","journal-title":"Neurol."},{"key":"1554_CR7","first-page":"6","volume":"65","author":"AS Gauchez","year":"2007","unstructured":"Gauchez AS, Pez E, Boutonnat J, Bourre JC, Pelletier L, Payan R, et al. Early detection of leptomeningeal metastasis in patients with metastatic breast carcinoma: validation of CA 15\u20133 measurement in cerebrospinal fluid. Ann Biol Clin. 2007;65:6\u2013653.","journal-title":"Ann Biol Clin"},{"issue":"2","key":"1554_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-009-9819-2","volume":"94","author":"MD Groves","year":"2009","unstructured":"Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neuro-Oncol. 2009;94(2):229\u201334.","journal-title":"J Neuro-Oncol"},{"key":"1554_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12032-008-9096-5","volume":"26","author":"G Orphanos","year":"2009","unstructured":"Orphanos G, Ioannidis G, Michael M, Kitrou G. Prostate-specific antigen in the cerebrospinal fluid: a marker of local disease. Med Oncol. 2009;26:2\u2013143.","journal-title":"Med Oncol"},{"issue":"3","key":"1554_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<543::AID-CNCR17>3.0.CO;2-4","volume":"77","author":"CH Rhodes","year":"1996","unstructured":"Rhodes CH, Glantz MJ, Glantz L, Lekos A, Sorenson GD, Honsinger C, et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer. 1996;77(3):543\u20138.","journal-title":"Cancer."},{"issue":"1","key":"1554_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ana.410380111","volume":"38","author":"FRACP RJFM","year":"1995","unstructured":"RJFM FRACP, George Krol MD, DLM D. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38(1):51\u20137.","journal-title":"Ann Neurol"},{"key":"1554_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-018-1232-z","volume":"19","author":"X Guo","year":"2019","unstructured":"Guo X, Cui J, Zhao Y, Han W, Zou Y, Gao R, et al. The therapeutic value of cerebrospinal fluid ctDNA detection by next-generation sequencing for meningeal carcinomatosis: a case report. BMC Neurol. 2019;19:1\u201338.","journal-title":"BMC Neurol"},{"issue":"10","key":"1554_CR13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1158\/1541-7786.mcr-16-0044","volume":"14","author":"S Volik","year":"2016","unstructured":"Volik S, Alcaide M, Morin RD, Collins C. Cell-free DNA (cfDNA): clinical significance and utility in Cancer shaped by emerging technologies. Mol Cancer Res. 2016;14(10):898\u2013908. https:\/\/doi.org\/10.1158\/1541-7786.mcr-16-0044.","journal-title":"Mol Cancer Res"},{"key":"1554_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary R, Kinde I, Agrawal N, Bartlett B, et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES. Sci Transl Med. 2014;6:224\u2013224ra24.","journal-title":"Sci Transl Med"},{"key":"1554_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2217\/cns-2018-0015","volume":"8","author":"DE Piccioni","year":"2019","unstructured":"Piccioni DE, Achrol AS, Kiedrowski LA, Banks KC, Boucher N, Barkhoudarian G, et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 2019;8:2\u2013CNS34. https:\/\/doi.org\/10.2217\/cns-2018-0015.","journal-title":"CNS Oncol"},{"key":"1554_CR16","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","volume":"6","author":"ML De","year":"2015","unstructured":"De ML, Mayor R, Ng CK, Weigelt B, Mart\u00ednezricarte F, Torrejon D, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.","journal-title":"Nat Commun"},{"key":"1554_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/jco.2011.29.27_suppl.11","volume":"29","author":"YS Li","year":"2018","unstructured":"Li YS, Jiang BY, Yang JJ, Zhang XC, Zhang Z, Ye JY, et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in Leptomeningeal metastases of EGFR-mutant non-small cell lung Cancer: a new medium of liquid biopsy. Ann Oncol Official J Eur Soc Med Oncol. 2018;29:11.","journal-title":"Ann Oncol Official J Eur Soc Med Oncol"},{"issue":"31","key":"1554_CR18","doi-asserted-by":"publisher","first-page":"9704","DOI":"10.1073\/pnas.1511694112","volume":"112","author":"Y Wang","year":"2015","unstructured":"Wang Y, Springer S, Zhang M, Mcmahon KW, Kinde I, Dobbyn L, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015;112(31):9704\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"1554_CR19","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/jco.2016.66.6487","volume":"34","author":"EI Pentsova","year":"2016","unstructured":"Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, et al. Evaluating Cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016;34(20):2404\u201315. https:\/\/doi.org\/10.1200\/jco.2016.66.6487.","journal-title":"J Clin Oncol"},{"key":"1554_CR20","first-page":"4","volume":"9","author":"X Cai","year":"2014","unstructured":"Cai X, Sheng J, Tang C, Nandakumar V, Ye H, Ji H, et al. Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing. Plos One. 2014;9:4\u2013e95228.","journal-title":"Plos One"},{"key":"1554_CR21","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.1038\/srep05907","volume":"4","author":"Z Xu","year":"2014","unstructured":"Xu Z, Huo X, Tang C, Ye H, Nandakumar V, Lou F, et al. Frequent KIT mutations in human gastrointestinal stromal tumors. Sci Rep. 2014;4:5907.","journal-title":"Sci Rep"},{"key":"1554_CR22","first-page":"6","volume":"9","author":"X Bai","year":"2014","unstructured":"Bai X, Zhang E, Ye H, Nandakumar V, Wang Z, Chen L, et al. PIK3CA and TP53 Gene Mutations in Human Breast Cancer Tumors Frequently Detected by Ion Torrent DNA Sequencing. Plos One. 2014;9:6\u2013e99306.","journal-title":"Plos One"},{"issue":"45","key":"1554_CR23","doi-asserted-by":"publisher","first-page":"16368","DOI":"10.1073\/pnas.0507904102","volume":"102","author":"F Diehl","year":"2005","unstructured":"Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7404","key":"1554_CR24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LAD Jr","year":"2012","unstructured":"Jr LAD, Williams R, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nat. 2012;486(7404):537\u201340.","journal-title":"Nat."},{"issue":"2","key":"1554_CR25","first-page":"266","volume":"1865","author":"VL Canzoniero","year":"2016","unstructured":"Canzoniero VL, Park BH. Use of cell free DNA in breast oncology. Biochim Biophys Acta. 2016;1865(2):266\u201374.","journal-title":"Biochim Biophys Acta"},{"key":"1554_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","volume":"404","author":"Leslie Calapre","year":"2017","unstructured":"Calapre L, Warburton L, Milward M, Ziman M, Gray ES. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 2017;404.","journal-title":"Cancer Letters"},{"key":"1554_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:5\u2013548.","journal-title":"Nat Med"},{"issue":"2","key":"1554_CR28","first-page":"394","volume":"1868","author":"A Creemers","year":"2017","unstructured":"Creemers A, Krausz S, Strijker M, Mj VDW, Soer EC, Reinten RJ, et al. Clinical value of ctDNA in upper-GI cancers: a systematic review and meta-analysis. Biochim Biophys Acta. 2017;1868(2):394\u2013403.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"1554_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.yexmp.2017.02.009","volume":"102","author":"C Corr\u00f2","year":"2017","unstructured":"Corr\u00f2 C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, et al. Detecting circulating tumor DNA in renal cancer: an open challenge. Exp Mol Pathol. 2017;102(2):255\u201361.","journal-title":"Exp Mol Pathol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1554-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1554-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1554-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T19:19:02Z","timestamp":1608232742000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1554-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1554"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1554-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.9575\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9575\/v2","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the Ethics Committee of the Second Hospital of Hebei Medical University. Written informed consent has been obtained from all patients or their legal surrogates.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"331"}}